<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4405775/" ref="ordinalpos=872&amp;ncbi_uid=7448428&amp;link_uid=PMC4405775" image-link="/pmc/articles/PMC4405775/figure/F1/" class="imagepopup">Figure 1.  From: Targeting NADPH Oxidases for the Treatment of Cancer and Inflammation. </a></div><br /><div class="p4l_captionBody">Dependence on signaling pathways based upon tumor suppressor status. Tumors that are deficient in p16ink4a are more likely to use a reactive oxygen/rac/NFkB signaling pathway, while tumors that have mutant p53 are more likely to use a noncanonical NFkB signaling pathway and phosphoinositol-3 kinase dependent but Akt independent pathway.</div></div>